Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1825968 | 0.91 | ADRB3 (0.59) | ADRB3ADRB2 | |
| SCHEMBL1825594 | 0.89 | ADRB3 (0.64) | ADRB3ADRB2 | |
| SCHEMBL1827259 | 0.89 | ADRB3 (0.68) | ADRB3 | |
| SCHEMBL1823924 | 0.80 | ADRB3 (0.62) | ADRB3ADRB2 | |
| SCHEMBL1826826 | 0.80 | ADRB3 (0.66) | ADRB3 | |
| SCHEMBL1824009 | 0.79 | ADRB3 (0.67) | ADRB3 | |
| SCHEMBL866010 | 0.77 | ADRB3 (0.60) | ADRB3ADRB2 | |
| Zinterol SCHEMBL30338438 | 0.76 | ADRB2 (1.00) | ADRB3ADRB2 | |
| Zinterol SCHEMBL119175 | 0.76 | ADRB2 (1.00) | ADRB3ADRB2 | |
| Zinterol SCHEMBL14452736 | 0.76 | ADRB2 (1.00) | ADRB3ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1761509-B1 | SUBSTITUTED CYCLOALKYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2011-05-04 | — | — | EP | disclosed |
| US-7563806-B2 | Substituted cycloalkyl derivatives, process for the manufacture thereof and use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-21 | — | — | US | disclosed |
| US-7563806-B2 | Substituted cycloalkyl derivatives, process for the manufacture thereof and use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-21 | — | — | US | disclosed |
| US-7423035-B2 | Substituted cycloalkyl derivatives, process for the manufacture thereof and use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-09 | — | — | US | disclosed |
| US-7423035-B2 | Substituted cycloalkyl derivatives, process for the manufacture thereof and use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-09 | — | — | US | disclosed |
| US-20080146554-A1 | Substituted Cycloalkyl Derivatives, Process for the Manufacture thereof and Use thereof as Medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-19 | — | — | US | disclosed |
| US-20080146554-A1 | Substituted Cycloalkyl Derivatives, Process for the Manufacture thereof and Use thereof as Medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-19 | — | — | US | disclosed |
| US-20050261286-A1 | Substituted cycloalkyl derivatives, process for the manufacture thereof and use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | US | disclosed |
| EP-1595873-A1 | Substituted cycloalkyl derivatives for the treatment of respiratory diseases | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146554-A1 | Substituted Cycloalkyl Derivatives, Process for the Manufacture thereof and Use thereof as Medicament | CHRM1, CHRM2, CHRM3 | ADRB3 39/4885ADRB2 83/4885 |
| US-20050261286-A1 | Substituted cycloalkyl derivatives, process for the manufacture thereof and use thereof as medicament | CHRM1, CHRM2, CHRM3 | ADRB3 39/4885ADRB2 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.